July 14, 2015

Efficacy and vitreous levels of topical NSAIDs

FSFrancesco SemeraroBrescia University ARAndrea RussoBrescia University EGElena GambicortiUniversity of Brescia

Key Points

Key points are not available for this paper at this time.

Abstract

A growing body of evidence suggests that NSAIDs may be beneficial in the treatment of age-related macular degeneration, diabetic retinopathy, and ocular tumors. Recent studies from our group and other authors have shown that the vitreous levels of NSAID exceed the median inhibitory concentration, which can significantly decrease vitreous PGE2 levels.

KI fragen

Bookmark

View Full Paper

Cite This Study

Semeraro et al. (Tue,) studied this question.

synapsesocial.com/papers/69da716aae64bec32b835e6b https://doi.org/https://doi.org/10.1517/17425247.2015.1068756

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Increased vasodilatory prostaglandin production in the diabetic rat retinal vasculature1999 · 52 citations
2Evaluation of four drugs for inhibition of paracentesis-induced blood-aqueous humor barrier breakdown in cats2011 · 20 citations
3Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) Study2009 · 343 citations
4Double-masked controlled clinical trial of 5% tolmetin versus 0.5% prednisolone versus 0.9% saline in acute endogenous nongranulomatous anterior uveitis.1982 · 24 citations
5Topical nepafenac for treatment of exudative age‐related macular degeneration2009 · 13 citations

KI fragen

Bookmark

View Full Paper